Compare Northrop Grumman Corporation (NOC) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs TG Therapeutics Inc — how do they compare? Northrop Grumman Corporation trades at $480.06 (market cap $68.83B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Northrop Grumman Corporation is far larger — about 8.4× TG Therapeutics Inc's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Northrop Grumman Corporation for 81 Days and TG Therapeutics Inc for 16 Days on average.
| NOC | TGTX | |
|---|---|---|
Market Cap | $68.83B | $8.16B |
Volume | 1,081,989 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $768.02 | $59.06 |
52-Week Low | $473.46 | $26.94 |
Typical Hold Time | 81 Days | 16 Days |
Enterprise Value | $82.81B | $8.37B |
Dividend Yield | 2.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $480.72, up 1.53% on the day, with a bearish technical signal from moving averages but strong fundamentals including a P/E of 15.4 and ROE of 26.96%. Recent quarterly EPS beats and a consensus analyst price target of $600.62 suggest upside potential, though the stock faces headwinds from Boeing's recent $20 billion Navy fighter contract win (Seeking Alpha, 2026-10-02).
The outlook for NOC is supported by a record backlog and defense budget tailwinds, but competitive pressures and execution risks on key programs like the B-21 bomber pose challenges. Analyst sentiment is predominantly bullish with 54% buy ratings, indicating confidence in long-term growth despite near-term volatility.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
